文献速递主动脉疾病

Ankura覆膜支架腔内修复肾下腹主动脉瘤的结局

Outcomes of the Ankura Stent Graft for Endovascular Repair of Infrarenal Abdominal Aortic Aneurysm.
PubMed 文献 · J Endovasc Ther · 2023-06-11

这项回顾性队列研究纳入2015年1月至2021年11月在一家三级血管中心接受Ankura覆膜支架择期EVAR的116例患者,评估技术成功、死亡率和肾功能影响。原发和继发技术成功率分别为95.7%和100%,30天死亡率为0%,动脉瘤相关死亡率为2.6%;12个月eGFR较术前显著下降。

要点

  • Ankura支架择期EVAR的30天死亡率为0%,动脉瘤相关死亡率为2.6%。
  • Ⅰ型内漏发生率为5%,Ⅱ型内漏为13%,髂支支架通畅率为100%。
  • 12个月eGFR由术前73.69 mL/min/1.73 m2降至66.66 mL/min/1.73 m2(p<0.001)。

核心结论

  • Ankura覆膜支架显示出有效的耐久性,动脉瘤相关死亡率低且髂支通畅率高。
  • 本研究中择期EVAR与12个月时肾功能显著下降相关。
  • 需要更大样本系列研究评估Ankura覆膜支架的长期安全性和有效性。

研究设计与样本

  • 回顾性队列研究,纳入2015年1月至2021年11月在一家三级血管中心接受Ankura覆膜支架择期EVAR的全部患者。
  • 排除破裂性肾下和近肾主动脉瘤患者,所有患者解剖上符合使用说明书(IFU)。
  • 共116例患者,平均年龄71.1岁,男性占96.5%,平均动脉瘤直径62.3 mm,中位随访34个月(2-72个月)。
  • 随访包括术后1个月、12个月及此后每年CTA(若无内漏)。

主要发现

  • 原发和继发技术成功率分别为95.7%和100%。
  • 总体Ⅰ型内漏为5%(近端2例,远端3例),Ⅱ型内漏为13%。
  • 30天死亡率和并发症发生率分别为0%和5.2%。
  • 随访期间全因死亡率为13.9%(n=16),动脉瘤相关死亡率为2.6%(n=3);髂支支架通畅率为100%。
  • 免于再干预率2年时为98.2%,4年和6年时均为97.4%;术前eGFR 73.69 mL/min/1.73 m2 vs 术后12个月66.66 mL/min/1.73 m2(p<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需要更大样本系列研究评估Ankura覆膜支架的长期安全性和有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The purpose of this retrospective cohort study is to report outcomes of endovascular aortic repair (EVAR) with the novel endograft, Ankura (Lifetech Scientific, Shenzen, China). METHODS: We identified all patients who underwent elective EVAR with Ankura stent graft in a tertiary unit from January 2015 to November 2021. Patients with ruptured infrarenal and juxtarenal aortic aneurysms were excluded from the study. All patients were anatomically suitable according to the instructions for use (IFU). Follow-up (FU) included computed tomography angiography (CTA) at 1 month, 12 months, and yearly thereafter if endoleak (EL) was not present. Primary outcomes included technical success (primary and secondary) and 30-day overall mortality and morbidity. Secondary outcomes included late overall and aneurysm-related mortality as well as influence of suprarenal fixation of the endograft on renal function at 12 months using eGFR (CKI-EPI formula). RESULTS: The Ankura endograft was successfully implanted in 116 patients (mean age=71.1 years, 96.5% male). Mean aneurysm diameter was 62.3 mm. Median FU was 34 months (2-72 months). Primary and secondary technical success were 95.7% and 100%, respectively. Overall type I EL was 5% (2 proximal, 3 distal) and type II EL was 13%. Thirty days mortality and morbidity were 0% and 5.2%, respectively. All-cause mortality during FU was 13.9% (n=16); aneurysm-related mortality was 2.6% (n=3). Limb endograft patency was 100%. Freedom from reintervention was 98.2% at 2 years, and 97.4% at 4 and 6 years respectively. There was a statistically significant difference between preoperative (73.69 mL/min/1.73 m2) and postoperative (66.66 mL/min/1.73 m2) eGFR at 12 months (p<0.001). CONCLUSION: Ankura endograft has demonstrated an efficacious durability with low aneurysm-related mortality and high iliac limb patency rate. Elective EVAR is associated with significant decline in renal function at 12 months in our study. Larger series studies are necessary to evaluate long-term safety and efficacy of Ankura endograft.Clinical ImpactAnkura stent graft is a novel PTFE endograft with suprarenal fixation for infrarenal aneurysm repair. This retrospective cohort study of 116 patients provide a first "picture" of Ankura safety and efficacy in a European tertiary vascular center. High technical success rate, low aneurysm related mortality and high limb patency rate are the main findings of the study with a negative impact of suprarenal fixation on kidney function during follow up.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Tigkiropoulos K, Abatzis-Papadopoulos M, Papoutsis I, et al. Outcomes of the Ankura Stent Graft for Endovascular Repair of Infrarenal Abdominal Aortic Aneurysm. J Endovasc Ther. 2023. PMID: 37303166. doi:10.1177/15266028231179590

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。